Abstract:Pediatric brain tumors are the second most common malignancy of childhood after acute leukemia and the number one cause of cancer-related mortality1. Over the past decade, advanced molecular diagnostics have led to the discovery of new molecularly-defined tumor types with prognostic and therapeutic implications. Methylation profiles, whole genome sequencing, and transcriptomics have defined subgroups and revealed heterogeneity within commonly defined tumor entities2,3. These findings have also revealed important differences between adult and pediatric brain tumors of similar histology. The majority of pediatric low grade gliomas (pLGG) are defined by alterations in the mitogen-activated protein kinase (MAPK) pathway including BRAFV600E point mutation, K1AA1549-BRAF fusion, and FGFR1 alterations as opposed to IDH1/2 mutations and 1p/19q co-deletion seen more frequently in adult low grade gliomas4. These findings have led to targeted therapies, namely BRAF and MEK inhibitors, which are currently being evaluated in phase III clinical trials and may soon supplant chemotherapy as standard of care for pLGG's. While targeted therapy trials for pediatric brain tumors have had significant success, immunotherapy remains a challenge in a group of tumors with generally lower mutational burden compared to adult tumors and relatively "cold" immune microenvironment. Despite this, a wide array of immunotherapy trials including vaccine therapies, immune checkpoint blockade, chimeric antigen receptor (CAR) T cells, and viral therapies are on-going. Unique to pediatrics, multiple clinical trials have sought to answer the question of whether the most malignant pediatric brain tumors in the youngest patients can be successfully treated with high dose chemotherapy in lieu of radiation to avoid devastating long-term neurocognitive deficits. Due to the collaborative work of multiple pediatric neuro-oncology consortiums, the recent history of pediatric brain tumor research is one of efficient translation from bench to bedside in a rare group of tumors resulting in significant progress in the field. Here, advances in the areas of molecular characterization, targeted and immune-based therapies, and reduction in long term co-morbidities will be reviewed.

Use of External Control Cohorts in Pediatric Brain Tumor Clinical Trials

Considerations on Design and Analysis of External Control in Pediatric Oncology

Leveraging external control data in the design and analysis of neuro-oncology trials: Pearls and perils

Statistical approaches for the integration of external controls in a cystic fibrosis clinical trial: a simulation and an application

Framework for the Use of External Controls to Evaluate Treatment Outcomes in Precision Oncology Trials

Trial Design Challenges and Approaches for Precision Oncology in Rare Tumors: Experiences of the Children's Oncology Group

How to improve the quality of comparisons using external control cohorts in single-arm clinical trials?

Applying the estimand and target trial frameworks to external control analyses using observational data: a case study in the solid tumor setting

Evaluating Scholastic Achievement in Pediatric Brain Tumor Survivors Compared With Healthy Controls

Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers

Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations

Considerations for master protocols using external controls

Externally Controlled Studies Using Real-World Data in Patients With Hematological Cancers: A Systematic Review

Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial

Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae

Implementation of multi-site neurocognitive assessments within a pediatric cooperative group: Can it be done?

Use of Non-concurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion

Bayesian Nonparametric Common Atoms Regression for Generating Synthetic Controls in Clinical Trials

The Next Horizon of Drug Development: External Control Arms and Innovative Tools to Enrich Clinical Trial Data

The use of external controls: To what extent can it currently be recommended?

Social Determinants of Health and Associations With Outcomes in Pediatric Patients With Brain Tumors